Tiansheng Pharmaceutical Group Co

Tiansheng Pharmaceutical Group Co Operating Cash Flow

The Operating Cash Flow of Tiansheng Pharmaceutical Group Co (002872.SZ) as of Oct 26, 2026 is 42.97 M CNY. In the previous year, Operating Cash Flow was 50.15 M CNY — a change of -14.31% (lower).

Operating Cash Flow

42.97 MCNY

YoY

-14.31%

Last updated:

Operating Cash Flow of Tiansheng Pharmaceutical Group Co is 2025 42.97 M CNY. Operating Cash Flow of Tiansheng Pharmaceutical Group Co was 2024 50.15 M CNY. It decreases by -14.31% lower compared to the previous year.

The Tiansheng Pharmaceutical Group Co Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
153.99 M CNY
Jan 1, 2019
144.21 M CNY
Jan 1, 2020
189.75 M CNY
Jan 1, 2021
18.97 M CNY
Jan 1, 2022
89.18 M CNY
Jan 1, 2023
-24.56 M CNY
Jan 1, 2024
50.15 M CNY
Jan 1, 2025
42.97 M CNY
The Tiansheng Pharmaceutical Group Co Operating Cash Flow history
YEAROperating Cash FlowYoY
42.97 MCNY-14.31%
50.15 MCNY-304.17%
-24.56 MCNY-127.54%
89.18 MCNY+370.09%
18.97 MCNY-90.00%
189.75 MCNY+31.58%
144.21 MCNY-6.35%
153.99 MCNY-376.22%
-55.75 MCNY-111.00%
506.68 MCNY+137.28%
213.54 MCNY+11.22%
191.99 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tiansheng Pharmaceutical Group Co Stock analysis

What does Tiansheng Pharmaceutical Group Co do? Tiansheng Pharmaceutical Group Co., Ltd. generates revenue through the manufacturing and distribution of pharmaceutical products primarily within the domestic market. Its main products include pediatric lung cough particles, erythromycin enteric-coated capsules, silver ginseng Tongluo capsules, Salvia granules, Shugan Yi spleen granules, compound Ganoderma lucidum granules, Xiangdan injection, Qi and Diabetes tablets, liver capsule, Ling Jing capsule, lungs of nuclear paste, and Shen Qi Yi lung pill. The company focuses on domestic sales, targeting consumers seeking traditional Chinese medicine solutions for respiratory and digestive health. The firm's product portfolio emphasizes traditional Chinese medicine formulations, with specific offerings like Shugan Yi spleen granules for digestive issues and Ling Jing capsule for respiratory conditions. These products are distributed through domestic channels, catering to a market segment that prefers herbal remedies over conventional pharmaceuticals. Tiansheng's revenue stream is derived from the sale of these branded pharmaceutical items to pharmacies and healthcare providers within China. Tiansheng Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tiansheng Pharmaceutical Group Co stock

Operating Cash Flow of Tiansheng Pharmaceutical Group Co is 42.97 M CNY in 2025.

Operating Cash Flow of Tiansheng Pharmaceutical Group Co changed from 50.15 M CNY to 42.97 M CNY, representing a -14.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Tiansheng Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Tiansheng Pharmaceutical Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Tiansheng Pharmaceutical Group Co

All Key Metrics — Tiansheng Pharmaceutical Group Co